{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:40:38Z","timestamp":1780389638613,"version":"3.54.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007352","name":"Staatssekretariat f\u00fcr Bildung, Forschung und Innovation","doi-asserted-by":"publisher","award":["23.00413"],"award-info":[{"award-number":["23.00413"]}],"id":[{"id":"10.13039\/501100007352","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.euroneuro.2025.01.007","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:33:21Z","timestamp":1740108801000},"page":"58-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Lack of transparency on baseline pharmacological treatments in Clinical High-Risk for psychosis (CHR-P) may degrade precision: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3709-4111","authenticated-orcid":false,"given":"Andrea","family":"Raballo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3306-8197","authenticated-orcid":false,"given":"Michele","family":"Poletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Preti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2025.01.007_bib0001","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.schres.2020.10.001","article-title":"Depression: an actionable outcome for those at clinical high-risk","volume":"227","author":"Addington","year":"2021","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.euroneuro.2025.01.007_bib58","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/NMD.0000000000000290","article-title":"North American Prodrome Longitudinal Study (NAPLS 2): The Prodromal Symptoms","volume":"203","author":"Addington","year":"2015","journal-title":"J. Nerv. Mental Dis."},{"issue":"4","key":"10.1016\/j.euroneuro.2025.01.007_bib0002","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"issue":"2","key":"10.1016\/j.euroneuro.2025.01.007_bib0003","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jphys.2020.02.011","article-title":"Research note: in a meta-analysis, the I2 index does not tell us how much the effect size varies across studies","volume":"6","author":"Borenstein","year":"2020","journal-title":"J. Physiother."},{"issue":"7109","key":"10.1016\/j.euroneuro.2025.01.007_bib0004","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2025.01.007_bib0005","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1214\/aoms\/1177729756","article-title":"Trasformations related to the angular and the square root","volume":"4","author":"Freeman","year":"1950","journal-title":"Ann. Math. Statist."},{"key":"10.1016\/j.euroneuro.2025.01.007_bib0006","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.schres.2021.06.030","article-title":"Antipsychotics and Attenuated Psychosis Syndrome: transdiagnostic assessment and discontinuation strategies","volume":"243","author":"Fusar-Poli","year":"2022","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.euroneuro.2025.01.007_bib0007","article-title":"New generation antidepressants for depression in children and adolescents: a network meta-analysis","volume":"5","author":"Hetrick","year":"2021","journal-title":"Cochr. Datab. System. Rev."},{"issue":"2","key":"10.1016\/j.euroneuro.2025.01.007_bib0008","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","article-title":"Assessing heterogeneity in meta-analysis: q statistic or I2 index?","volume":"11","author":"Huedo-Medina","year":"2006","journal-title":"Psychol. Method."},{"key":"10.1016\/j.euroneuro.2025.01.007_bib0009","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.euroneuro.2023.03.001","article-title":"The elephant in the room: medication as confounder","volume":"71","author":"Ilzarbe","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.euroneuro.2025.01.007_bib0010","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.euroneuro.2025.01.007_bib0011","first-page":"193","article-title":"Precision medicine for psychosis: a revolution at the interface of psychiatry and neurology","volume":"19","author":"Keshavan","year":"2023","journal-title":"Nat. Rev. Neurol."},{"issue":"12","key":"10.1016\/j.euroneuro.2025.01.007_bib0012","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1001\/jamapsychiatry.2021.2500","article-title":"Pragmatic Precision Psychiatry-A new direction for optimizing treatment selection","volume":"78","author":"Kessler","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"17","key":"10.1016\/j.euroneuro.2025.01.007_bib0013","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/sim.1482","article-title":"Improved tests for a random effects meta-regression with a single covariate","volume":"22","author":"Knapp","year":"2003","journal-title":"Stat. Med."},{"issue":"4","key":"10.1016\/j.euroneuro.2025.01.007_bib0014","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.rcp.2019.10.003","article-title":"Neuroleptic malignant syndrome in children and adolescents: systematic review of Case reports. S\u00edndrome neurol\u00e9ptico maligno en ni\u00f1os y adolescentes: revisi\u00f3n sistem\u00e1tica de reportes de caso","volume":"50","author":"Le\u00f3n-Amenero","year":"2021","journal-title":"Rev. Colomb. Psiquiatr."},{"key":"10.1016\/j.euroneuro.2025.01.007_bib0015","series-title":"Structured Interview for Prodromal Symptoms (SIPS)","author":"McGlashan","year":"2001"},{"issue":"8","key":"10.1016\/j.euroneuro.2025.01.007_bib0016","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/00048674211009620","article-title":"Monitoring of metabolic side-effects in children and adolescents prescribed antipsychotic medication: a systematic review","volume":"55","author":"Mead","year":"2021","journal-title":"Austr. N. Zeal. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.01.007_bib0017","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2025.01.007_bib0018","unstructured":"National Institute for Health and Care Excellence. Psychosis and schizophrenia and adults: prevention and management, 2014."},{"key":"10.1016\/j.euroneuro.2025.01.007_bib0019","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol. Rep."},{"key":"10.1016\/j.euroneuro.2025.01.007_bib0020","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2025.01.007_bib0021","article-title":"Subgroups of clinical high risk for psychosis based on baseline antipsychotic exposure: clinical and outcome comparisons across a 2-year follow-up period","author":"Pelizza","year":"2024","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.euroneuro.2025.01.007_bib0022","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/eip.13434","article-title":"Baseline antipsychotic prescription and short-term outcome indicators in individuals at clinical high-risk for psychosis: findings from the Parma At-risk Mental States (PARMS) program","volume":"18","author":"Pelizza","year":"2024","journal-title":"Early Interv. Psychiatry"},{"issue":"10","key":"10.1016\/j.euroneuro.2025.01.007_bib0023","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00228-019-02711-3","article-title":"Prescription prevalence of psychotropic drugs in children and adolescents: an analysis of international data","volume":"75","author":"Piovani","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2025.01.007_bib0024","article-title":"Clinical High-risk for psychosis (CHR-P) circa 2024: synoptic analysis and synthesis of contemporary treatment guidelines","volume":"100","author":"Poletti","year":"2024","journal-title":"Asia. J. Psychiatr."},{"issue":"4","key":"10.1016\/j.euroneuro.2025.01.007_bib0025","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/eip.13158","article-title":"Antipsychotics are related to psychometric conversion to psychosis in ultra-high-risk youth","volume":"16","author":"Preti","year":"2022","journal-title":"Early Interv. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.01.007_bib0026","series-title":"R: A language and Environment For Statistical Computing","year":"2023"},{"issue":"7","key":"10.1016\/j.euroneuro.2025.01.007_bib0027","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/jamapsychiatry.2024.0178","article-title":"Baseline antipsychotic dose and transition to psychosis in individuals at clinical high risk: a systematic review and meta-analysis","volume":"81","author":"Raballo","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2025.01.007_bib0028","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1017\/S0033291719003337","article-title":"Overlooking the transition elephant in the ultra-high-risk room: are we missing functional equivalents of transition to psychosis?","volume":"52","author":"Raballo","year":"2022","journal-title":"Psychol. Med."},{"issue":"10","key":"10.1016\/j.euroneuro.2025.01.007_bib0029","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1017\/S0033291722001428","article-title":"Do antidepressants prevent transition to psychosis in individuals at clinical high-risk (CHR-P)? Systematic review and meta-analysis","volume":"53","author":"Raballo","year":"2023","journal-title":"Psychol. Med."},{"issue":"1","key":"10.1016\/j.euroneuro.2025.01.007_bib0030","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41398-023-02405-6","article-title":"The temporal dynamics of transition to psychosis in individuals at clinical high-risk (CHR-P) shows negative prognostic effects of baseline antipsychotic exposure: a meta-analysis","volume":"13","author":"Raballo","year":"2023","journal-title":"Transl. Psychiatry"},{"issue":"14","key":"10.1016\/j.euroneuro.2025.01.007_bib0031","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1017\/S0033291723002180","article-title":"Baseline benzodiazepine exposure is associated with greater risk of transition in clinical high-risk for psychosis (CHR-P): a meta-analysis","volume":"53","author":"Raballo","year":"2023","journal-title":"Psychol. Med."},{"issue":"5","key":"10.1016\/j.euroneuro.2025.01.007_bib0032","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1177\/0004867420984836","article-title":"Antipsychotic treatment in clinical high risk for psychosis: protective, iatrogenic or further risk flag?","volume":"55","author":"Raballo","year":"2021","journal-title":"Austr. New Zeal. J. Psychiatry"},{"issue":"12","key":"10.1016\/j.euroneuro.2025.01.007_bib0033","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamapsychiatry.2020.1634","article-title":"Attenuated psychosis syndrome or pharmacologically Attenuated first-episode psychosis?: an undesirably widespread confounder","volume":"77","author":"Raballo","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.euroneuro.2025.01.007_bib0034","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.biopsych.2021.01.020","article-title":"Individualized diagnostic and prognostic models for psychosis risk syndromes: do not underestimate antipsychotic exposure","volume":"90","author":"Raballo","year":"2021","journal-title":"Biol. Psychiatry"},{"issue":"9","key":"10.1016\/j.euroneuro.2025.01.007_bib0035","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/ijnp\/pyab030","article-title":"Negative prognostic effect of baseline antipsychotic exposure in clinical high risk for psychosis (CHR-P): is pre-test risk enrichment the hidden culprit?","volume":"24","author":"Raballo","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.euroneuro.2025.01.007_bib0036","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1055\/s-2008-1038155","article-title":"Das Basel Screening Instrument f\u00fcr Psychosen (BSIP): entwicklung, aufbau, reliabilit\u00e4t und validit\u00e4t [The Basel Screening Instrument for Psychosis (BSIP): development, structure, reliability and validity]","volume":"76","author":"Riecher-R\u00f6ssler","year":"2008","journal-title":"Fortschr. Neurol. Psychiatr."},{"key":"10.1016\/j.euroneuro.2025.01.007_bib0037","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.neubiorev.2021.02.032","article-title":"Towards clinical application of prediction models for transition to psychosis: a systematic review and external validation study in the PRONIA sample","volume":"125","author":"Rosen","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"4","key":"10.1016\/j.euroneuro.2025.01.007_bib0038","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.biopsych.2020.02.009","article-title":"Individualized diagnostic and prognostic models for patients with psychosis risk syndromes: a meta-analytic view on the State of the art","volume":"88","author":"Sanfelici","year":"2020","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2025.01.007_bib0039","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.eurpsy.2015.01.013","article-title":"EPA guidance on the early intervention in clinical high risk states of psychoses","volume":"30","author":"Schmidt","year":"2015","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.01.007_bib0040","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.euroneuro.2023.07.004","article-title":"The clinical high-risk of psychosis approach as an emerging model for precision prevention in psychiatry","volume":"76","author":"Schultze-Lutter","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.01.007_bib0041","series-title":"Meta-Analysis With R","author":"Schwarzer","year":"2015"},{"issue":"3","key":"10.1016\/j.euroneuro.2025.01.007_bib0042","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/jrsm.1348","article-title":"Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions","volume":"10","author":"Schwarzer","year":"2019","journal-title":"Res. Synth. Method."},{"issue":"8","key":"10.1016\/j.euroneuro.2025.01.007_bib0043","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002635","article-title":"Benzodiazepine prescribing for children, adolescents, and young adults from 2006 through 2013: a total population register-linkage study","volume":"15","author":"Sidorchuk","year":"2018","journal-title":"PLoS Med."},{"issue":"2","key":"10.1016\/j.euroneuro.2025.01.007_bib0044","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/wps.20765","article-title":"Safety of 80 antidepressants, antipsychotics, anti-attention-deficit\/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects","volume":"19","author":"Solmi","year":"2020","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.01.007_bib0045","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fpsyt.2020.00018","article-title":"Duty to warn: antidepressant black box suicidality warning is empirically justified","volume":"11","author":"Spielmans","year":"2020","journal-title":"Front. Psychiatry"},{"issue":"7","key":"10.1016\/j.euroneuro.2025.01.007_bib0046","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1001\/jamapsychiatry.2018.0375","article-title":"Precision psychiatry-will genomic medicine lead the way?","volume":"75","author":"Stein","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"29","key":"10.1016\/j.euroneuro.2025.01.007_bib0047","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1002\/sim.4040","article-title":"Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data","volume":"29","author":"Stijnen","year":"2010","journal-title":"Stat. Med."},{"issue":"9","key":"10.1016\/j.euroneuro.2025.01.007_bib0048","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1093\/ijnp\/pyy048","article-title":"Suicidal ideation and Suicidal behavior as rare adverse events of antidepressant medication: current report from the AMSP Multicenter Drug Safety Surveillance Project","volume":"21","author":"St\u00fcbner","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2025.01.007_bib0049","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1164","article-title":"Methods to estimate the between-study variance and its uncertainty in meta-analysis","volume":"7","author":"Veroniki","year":"2016","journal-title":"Res. Synth. Method."},{"issue":"2","key":"10.1016\/j.euroneuro.2025.01.007_bib0050","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/jrsm.11","article-title":"Outlier and influence diagnostics for meta-analysis","volume":"1","author":"Viechtbauer","year":"2010","journal-title":"Res. Synth. Method."},{"issue":"3","key":"10.1016\/j.euroneuro.2025.01.007_bib0051","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the Metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.euroneuro.2025.01.007_bib0052","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3389\/fpsyt.2020.00478","article-title":"Antidepressant prescribing and suicide\/self-harm by young Australians: regulatory warnings, contradictory advice, and long-term trends","volume":"11","author":"Whitely","year":"2020","journal-title":"Front. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.euroneuro.2025.01.007_bib0053","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.schres.2013.05.019","article-title":"Psychotropic medication use in youth at high risk for psychosis: comparison of baseline data from two research cohorts 1998-2005 and 2008-2011","volume":"148","author":"Woods","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2025.01.007_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2020.113098","article-title":"Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia","volume":"402","author":"Yoshida","year":"2021","journal-title":"Behav. Brain Res."},{"issue":"11\u201312","key":"10.1016\/j.euroneuro.2025.01.007_bib0055","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1080\/j.1440-1614.2005.01714.x","article-title":"Mapping the onset of psychosis: the Comprehensive Assessment of At-risk mental states","volume":"39","author":"Yung","year":"2005","journal-title":"Austr. N. Zeal. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2025.01.007_bib0056","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.21m14092","article-title":"Antipsychotic exposure in clinical high risk of psychosis: empirical insights from a large cohort study","volume":"83","author":"Zeng","year":"2022","journal-title":"J. Clin. Psychiatry"},{"issue":"7","key":"10.1016\/j.euroneuro.2025.01.007_bib0057","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1177\/0004867420917449","article-title":"Real-world effectiveness of antipsychotic treatment in psychosis prevention in a 3-year cohort of 517 individuals at clinical high risk from the SHARP (ShangHai At Risk for Psychosis)","volume":"54","author":"Zhang","year":"2020","journal-title":"Austr. N. Zeal. J. Psychiatry"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X25000203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X25000203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:42:06Z","timestamp":1762321326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X25000203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":58,"alternative-id":["S0924977X25000203"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2025.01.007","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lack of transparency on baseline pharmacological treatments in Clinical High-Risk for psychosis (CHR-P) may degrade precision: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2025.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}